Follow
Zachary Hunter, PhD
Zachary Hunter, PhD
Dana-Farber Cancer Institute - Bing Center for WM
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, ...
New England Journal of Medicine 367 (9), 826-833, 2012
14752012
Ibrutinib in previously treated Waldenström’s macroglobulinemia
SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ...
New England Journal of Medicine 372 (15), 1430-1440, 2015
9982015
The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B …
ZR Hunter, L Xu, G Yang, Y Zhou, X Liu, Y Cao, RJ Manning, C Tripsas, ...
Blood, The Journal of the American Society of Hematology 123 (11), 1637-1646, 2014
5062014
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele …
L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ...
Blood, The Journal of the American Society of Hematology 121 (11), 2051-2058, 2013
4492013
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia
SP Treon, Y Cao, L Xu, G Yang, X Liu, ZR Hunter
Blood, The Journal of the American Society of Hematology 123 (18), 2791-2796, 2014
4202014
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia
G Yang, Y Zhou, X Liu, L Xu, Y Cao, RJ Manning, CJ Patterson, ...
Blood, The Journal of the American Society of Hematology 122 (7), 1222-1232, 2013
4082013
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
E Hatjiharissi, L Xu, DD Santos, ZR Hunter, BT Ciccarelli, S Verselis, ...
Blood, the Journal of the American Society of Hematology 110 (7), 2561-2564, 2007
3152007
MYD88 mutations and response to ibrutinib in Waldenström's macroglobulinemia
SP Treon, L Xu, Z Hunter
New England Journal of Medicine 373 (6), 584-586, 2015
2672015
The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia
Y Cao, ZR Hunter, X Liu, L Xu, G Yang, J Chen, CJ Patterson, ...
Leukemia 29 (1), 169-176, 2015
2402015
Characterization of familial Waldenström's macroglobulinemia
SP Treon, ZR Hunter, A Aggarwal, EP Ewen, S Masota, C Lee, DD Santos, ...
Annals of Oncology 17 (3), 488-494, 2006
2252006
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248
SP Treon, ZR Hunter, J Matous, RM Joyce, B Mannion, R Advani, D Cook, ...
Clinical cancer research 13 (11), 3320-3325, 2007
2202007
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs
X Leleu, J Soumerai, A Roccaro, E Hatjiharissi, ZR Hunter, R Manning, ...
Journal of Clinical Oncology 27 (2), 250-255, 2009
1942009
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
SP Treon, CK Tripsas, K Meid, S Kanan, P Sheehy, S Chuma, L Xu, ...
Blood, The Journal of the American Society of Hematology 124 (4), 503-510, 2014
1912014
Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia
SP Treon, J Gustine, K Meid, G Yang, L Xu, X Liu, M Demos, A Kofides, ...
Journal of Clinical Oncology 36 (27), 2755-2761, 2018
1842018
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia
SP Treon, AR Branagan, Z Hunter, D Santos, O Tournhilac, KC Anderson
Annals of oncology 15 (10), 1481-1483, 2004
1752004
Thalidomide and rituximab in Waldenstrom macroglobulinemia
SP Treon, JD Soumerai, AR Branagan, ZR Hunter, CJ Patterson, ...
Blood, The Journal of the American Society of Hematology 112 (12), 4452-4457, 2008
1572008
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia
SP Treon, JD Soumerai, AR Branagan, ZR Hunter, CJ Patterson, ...
Clinical cancer research 15 (1), 355-360, 2009
1502009
Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia
L Xu, ZR Hunter, N Tsakmaklis, Y Cao, G Yang, J Chen, X Liu, S Kanan, ...
British journal of haematology 172 (5), 735-744, 2016
1472016
Overall survival and competing risks of death in patients with W aldenström macroglobulinaemia: an analysis of the S urveillance, E pidemiology and E nd R esults database
JJ Castillo, AJ Olszewski, S Kanan, K Meid, ZR Hunter, SP Treon
British Journal of Haematology 169 (1), 81-89, 2015
1462015
Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies
SP Treon, L Xu, ML Guerrera, C Jimenez, ZR Hunter, X Liu, M Demos, ...
Journal of Clinical Oncology 38 (11), 1198-1208, 2020
1452020
The system can't perform the operation now. Try again later.
Articles 1–20